A Pilot Study of Radiation Therapy in Combination With Pembrolizumab in Patients With Metastatic Renal Cell Cancer
Conclusion:
Combining RT with pembrolizumab in pretreated mRCC is well-tolerated and appears to have comparable efficacy with single-agent nivolumab.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Genitourinary Source Type: research
More News: Cancer | Cancer & Oncology | Kidney Cancer | Radiation Therapy | Renal Cell Carcinoma | Study | Thrombocytopenia